Dr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric Cancer

“What we showed is that, in the first 13 patients [with stage I disease] accrued to the study, there were 2 confirmed and an additional 2 unconfirmed partial responses exceeding the predefined threshold.”

Rachel N. Grisham, MD, an associate attending physician at Memorial Sloan Kettering Cancer Center; section head of Ovarian Cancer; and director of Gynecologic Medical Oncology, at Memorial Sloan Kettering Cancer Center Westchester, discusses interim results from a phase 2 study (NCT05787561), which evaluated avutometinib (VS-6766) plus defactinib (VS-6063) in patients with advanced or recurrent gynecologic mesonephric cancer.